We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.80 | 0.80 | 0.80 | 198,696 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.40 | 1.45M |
Date | Subject | Author | Discuss |
---|---|---|---|
26/8/2020 14:31 | oioi.. rockets getting wheeled out to launchpad Breaking out n ready to test 20 Thanks y’all | rocket fuel | |
26/8/2020 09:25 | Expect to see the usual big buys hidden from view for an hour or two;) | ch1rp | |
26/8/2020 07:57 | For your information Nobb no vaccine nor silica based delivery system ever has. That's the point of medical trials:)News due anytime now on the agglomeration study results. This is a potential changer as upon success means nuvec has a much better chance of being effective using only one injection. Plus people forgetting Evotec started additional in vitro studies a couple of months ago to investigate if nuvec can transfect both murine intestinal cells and also human gastrointestinal mucosal/epithelial cells. This is key to assessing if the oral application route is feasible or not. Results could come any time. Updates also due on on viral vector manufacturing & partnership news. | ch1rp | |
26/8/2020 07:37 | It has never been in a human so how do they know it's great at delivering RNA. It's easy to do such experiments in inbred animal strains but ever so slightly different in outbred humans. The proof of the pudding is in the eating and this pudding hasn't even gone in the oven yet..... | nobbygnome | |
26/8/2020 07:29 | Love this post from Dangil on lseCOVID VaccineTue 16:19great piece by proactive https://www.proactiv | ch1rp | |
26/8/2020 07:10 | RedFlags everywhere | andymunchkin | |
26/8/2020 07:09 | PumpIs over exRampingCnts rDumping | andymunchkin | |
25/8/2020 09:48 | Whilst nothing goes up in a straight line, all of this is part of the general breakout to 16p happening right now. Great day yesterday. 12p base will be formed this week imo :))) | ch1rp | |
24/8/2020 15:53 | A good size buy now 79K, if it follows with another one the level 2 will be back as the high of the day | master rsi | |
24/8/2020 14:44 | Something a foot lads I reckons gla | jimbob999 | |
24/8/2020 14:41 | Easy does it. | jibba jabber | |
24/8/2020 13:45 | 3 MMs moving up and with that the share price also 12.25 v 12.75p 1 v 1 already up again has done to 3 v 4 at 12.25 v 13p | master rsi | |
24/8/2020 13:38 | Something leaked? Getting very heavy and 13p is about to go. Next on the chart is 18p. | genierub | |
24/8/2020 10:04 | Patience nobby it will happen. | charlie8888 | |
24/8/2020 10:01 | Pushing that upper boundary again. Pop coming. | hodhasharon | |
24/8/2020 10:01 | Positive news coming on stage 3. | letmepass | |
24/8/2020 09:51 | And how long before it actually goes into a human? All they have used so far is animals, cell lines and proteins such as ovalbumin. All this is of very limited relevance for in vivo use in an outbred human population! | nobbygnome | |
24/8/2020 09:31 | Not really. Just expecting a steady rise each week into news flows:Courtesy of John077 lseThose in vivo studies went ahead and the results were rns'ed 20/08/19. The results were very promising using both 2 &3 injections. They have since decided that a more monodisperse solution (all particles of a similar size) will result in less agglomeration (particles sticking together) and would make it much more likely to get better In vivo results using only one injection. The dispersion / agglomeration works have been ongoing and should be completed very soon. All looking good.From 06/07 rns it looks like the investigations into the oral applications are currently at the in-vitro phase Maz:'To that end the Company will working with Evotec to undertake some preliminary in vitro studies to establish first that Nuvec® can be optimised to transfect murine intestinal cells and, secondly, that it can transfect human gastrointestinal mucosal/epithelial cells. Without being able to efficiently transfect gut cells, any oral application would not be possible, so it is essential to complete these studies prior to progressing any further with this initiative.'Assuming this study was started immediately, we could be approx 45 days into these works so news could come at any time on this.Also awaiting further updates on:viral vector manufacturing the pre in-vivo studyDispersion / agglomeration worksOngoing potential commercial partner discussionsAll the above have the potential to be transformational.... | ch1rp | |
24/8/2020 09:24 | Is your crystal ball in for repairs? | dplewis1 | |
24/8/2020 09:22 | Level 2 2 at 12p bid now | master rsi | |
24/8/2020 08:54 | Are you expecting news this week? | hodhasharon | |
24/8/2020 08:43 | Level 2 improving all the time, and many MMs have move +0.375 (3.19%) currently 2 at 11.75 and offer went from 12 to 12.50p now | master rsi | |
23/8/2020 11:41 | La la la.... blissfully unaware of all your troll arguments from now on. What a relief! Looking forward to news on all fronts:Courtesy of John077 lseThose in vivo studies went ahead and the results were rns'ed 20/08/19. The results were very promising using both 2 &3 injections. They have since decided that a more monodisperse solution (all particles of a similar size) will result in less agglomeration (particles sticking together) and would make it much more likely to get better In vivo results using only one injection. The dispersion / agglomeration works have been ongoing and should be completed very soon. All looking good.From 06/07 rns it looks like the investigations into the oral applications are currently at the in-vitro phase Maz:'To that end the Company will working with Evotec to undertake some preliminary in vitro studies to establish first that Nuvec® can be optimised to transfect murine intestinal cells and, secondly, that it can transfect human gastrointestinal mucosal/epithelial cells. Without being able to efficiently transfect gut cells, any oral application would not be possible, so it is essential to complete these studies prior to progressing any further with this initiative.'Assuming this study was started immediately, we could be approx 45 days into these works so news could come at any time on this.Also awaiting further updates on:viral vector manufacturing the pre in-vivo studyDispersion / agglomeration worksOngoing potential commercial partner discussionsAll the above have the potential to be transformational.... | ch1rp | |
23/8/2020 11:26 | Lol ok if you can't deal with facts just ignore them | dplewis1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions